Policy volatility and economic uncertainty are reshaping the pharmaceutical innovation landscape. From the Inflation Reduction Act in the USA, the EU pharma package, EU HTA legislation, and reshaped global reference pricing baskets following MFN actions from the US, investors and manufacturers alike are recalibrating their models for asset risk and reward. This panel brings together experts in finance, business development/licensing and commercialization to explore uncertainty—regulatory, political, and macroeconomic—impacts financing decisions for pipeline assets and go to market potential.
Tuesday, May 5, 09:00 - 09:45, room Delhi
| Name | Position | Institution |
|---|---|---|
| Jennifer Cain Birkmose | Vice President, Europe | Aesara |
| Name | Position | Institution |
|---|---|---|
| Sezai Tashkin | CEO | ViferaXS |
| Peter Braun | xecutive Director Biopharmaceutical CEO Roundtable, IFPMA, (exited) CEO | Targimmune Therapeutic AG |
| Karol Jarzabek | COO | Iorganbio |
A digital-forward Value & Market Access agency, AESARA develops innovative and trusted solutions that power transformative patient access. Specializing in: Strategic Consulting, Digital Solutions, Management Consulting Solutions, HEOR/MA Consulting, Operations Consulting, Value and Evidence, Oncology Value and Evidence, and Payer Center of Excellence
